Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of Oral Insulin N11005 in Healthy Subjects
NCT04975022Phase 1Completed
- Sponsor
- Beijing Hospital
- Start
- Dec 2019
- Primary completion
- Aug 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of N11005 in diabetes mellitus (DM) (2 arms), sponsored by Beijing Hospital. Primary endpoints: Maximum Concentration, Area Under the Curve 0-8 hours and 2 more. Started Dec 2019; status: completed.
02
Drugs
N11005
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT04975022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975022.